| Literature DB >> 30532142 |
Yasumasa Kawano1, Junichi Maruyama1, Ryo Hokama1, Megumi Koie1, Ryotaro Nagashima1, Kota Hoshino1, Kentaro Muranishi1, Maiko Nakashio1, Takeshi Nishida2, Hiroyasu Ishikura1.
Abstract
Recently, augmented renal clearance (ARC), which accelerates glomerular filtration of renally eliminated drugs thereby reducing the systemic exposure to these drugs, has started to receive attention. However, the clinical features associated with ARC are still not well understood, especially in the Japanese population. This study aimed to evaluate the clinical characteristics and outcomes of ARC patients with infections in Japanese intensive care unit (ICU) settings. We conducted a retrospective observational study from April 2013 to May 2017 at two tertiary level ICUs in Japan, which included 280 patients with infections (median age 74 years; interquartile range, 64-83 years). We evaluated the estimated glomerular filtration rate (eGFR) at ICU admission using the Japanese equation, and ARC was defined as eGFR >130 mL/min/1.73 m2. Multivariable logistic regression analysis was performed to identify the independent risk factors for ARC and to determine if it was a predictor of ICU mortality. In addition, a receiver operating curve (ROC) analysis was performed, and the area under the ROC (AUROC) was determined to examine the significant variables that predict ARC. In total, 19 patients (6.8%) manifested ARC. Multivariable logistic regression analysis identified younger age as an independent risk factor for ARC (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.91-0.96). However, ARC was not found to be a predictor of ICU mortality (OR, 0.57; 95% CI, 0.11-2.92). In addition, the AUROC of age was 0.79 (95% CI, 0.68-0.91), and the optimal cut off age for ARC was ≤63 years (sensitivity, 68.4%; specificity, 78.9%). The incidence of ARC was, therefore, low among patients with infections in the Japanese ICUs. Although younger age was associated with the incidence of ARC, it was not an independent predictor of ICU mortality.Entities:
Mesh:
Year: 2018 PMID: 30532142 PMCID: PMC6287846 DOI: 10.1371/journal.pone.0208742
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baselines characteristics, laboratory, therapeutic, and outcome data.
| Variables | All patients (n = 280) | ARC (n = 19) | Non-ARC (n = 261) | p value |
|---|---|---|---|---|
| Age (years), median (IQR) | 74 (64–83) | 46 (28–68) | 75 (65–83) | <0.05 |
| Sex, male, n (%) | 145 (51.8) | 9 (47.4) | 136 (52.1) | 0.81 |
| Mechanical ventilation, n (%) | 113 (40.4) | 12 (63.2) | 101 (38.7) | 0.05 |
| Diabetes mellitus, n (%) | 47 (16.8) | 4 (21.1) | 43 (16.5) | 0.54 |
| APACHE Ⅱ score, median (IQR) | 20 (16–25) | 23 (19–27) | 20 (16–24) | 0.06 |
| SOFA score, median (IQR) | 5 (3–7) | 6 (4–8) | 5 (3–7) | 0.17 |
| Serum albumin (g/dL), mean (SD) | 2.9 (0.76) | 2.8 (0.97) | 2.9 (0.75) | 0.52 |
| Serum CK (IU/L), median (IQR) | 71.5 (35–155) | 42 (25.5–76) | 74 (35–159) | 0.05 |
| Serum creatinine (mg/dL), median (IQR) | 0.7 (0.6–0.9) | 0.3 (0.3–0.37) | 0.74 (0.6–0.9) | <0.05 |
| Positive blood culture, n (%) | 71 (25.4) | 3 (15.8) | 68 (26.1) | 0.42 |
| Site of infection, n (%) | ||||
| Lung | 117 (41.8) | 13 (68.4) | 104 (39.8) | <0.05 |
| Abdomen | 80 (28.6) | 3 (15.8) | 77 (29.5) | 0.29 |
| Skin and soft tissue | 40 (14.3) | 3 (15.8) | 37 (14.2) | 0.74 |
| Urinary tract | 17 (6.1) | - | 17 (6.5) | - |
| Surgical site | 7 (2.5) | - | 7 (2.7) | - |
| Heart | 5 (1.8) | - | 5 (1.9) | - |
| Central nerve system | 4 (1.4) | - | 4 (1.5) | - |
| Catheter | 2 (0.7) | - | 2 (0.8) | - |
| Unknown | 8 (2.9) | - | 8 (3.1) | - |
| Antibiotic, n (%) | ||||
| Carbapenems | 137 (48.9) | 6 (31.6) | 131 (50.2) | 0.15 |
| Piperacillin-tazobactam | 63 (22.5) | 6 (31.6) | 57 (21.8) | 0.39 |
| Ampicillin-sulbactam | 45 (16.1) | 6 (31.6) | 39 (14.9) | 0.1 |
| Linezolid | 13 (4.6) | 1 (5.3) | 12 (4.6) | 0.61 |
| Glycopeptides | 13 (4.6) | - | 13 (5) | - |
| Clindamycin | 9 (3.2) | 2 (10.5) | 7 (2.7) | 0.12 |
| Fluoroquinolones | 7 (2.5) | - | 7 (2.7) | - |
| Cephalosporins | 6 (2.1) | 1 (5.3) | 5 (1.9) | 0.35 |
| Macrolides | 6 (2.1) | - | 6 (2.3) | - |
| Daptomycin | 3 (1.1) | 1 (5.3) | 2 (0.8) | 0.19 |
| Others | 8 (2.9) | - | 8 (3.1) | - |
| ICU-free days on Day 28, median (IQR) | 21 (12–25) | 19 (12–23) | 22 (12–25) | 0.23 |
| ICU mortality, n (%) | 27 (9.6) | 2 (10.5) | 25 (9.6) | 0.7 |
ARC, augmented renal clearance; IQR, interquartile range; APACHE, Acute Physiology, and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; SD, standard deviation; CK, creatine kinase; ICU, intensive care unit.
a The p values were evaluated by comparison between patients with and without ARC.
Comparison of bacteriological and outcome data in patients with positive blood culture, with and without ARC.
| Variables | ARC (n = 3) | Non-ARC (n = 68) | p-value |
|---|---|---|---|
| Microbiological examination, n (%) | |||
| Gram positive coccus | 2 (66.6) | 37 (54.4) | 1.0 |
| Gram-negative rods | - | 20 (29.4) | - |
| Gram-positive coccus and Fungus | 1 (33.3) | - | - |
| Fungus | - | 5 (7.4) | - |
| others | - | 6 (8.8) | - |
| ICU-free days on Day 28, median (IQR) | 19 (9.5–21) | 23 (13.8–25) | 0.24 |
| ICU mortality, n (%) | 1 (33.3) | 5 (7.4) | 0.24 |
ARC, augmented renal clearance; ICU, intensive care unit; IQR, interquartile range.
Proportions of patients falling into various eGFR ranges as assessed by the Japanese, CG, MDRD, and CKD-EPI equations.
| Japanese | CG | MDRD | CKD-EPI | |
|---|---|---|---|---|
| eGFR >130 mL/min/1.73 m2 | 19 (6.8) | 28 (10) | 57 (20.4) | 13 (4.6) |
| 130≥ eGFR >90 mL/min/1.73 m2 | 54 (19.3) | 55 (19.6) | 96 (34.3) | 109 (38.9) |
| 90≥ eGFR >60 mL/min/1.73 m2 | 124 (44.3) | 98 (35) | 106 (37.9) | 136 (48.6) |
| 60≥ eGFR >30 mL/min/1.73 m2 | 83 (29.6) | 97 (34.6) | 21 (7.5) | 22 (7.9) |
| 30≥ eGFR >15 mL/min/1.73 m2 | 0 | 2 (0.7) | 0 | 0 |
| eGFR ≤15 mL/min/1.73 m2 | 0 | 0 | 0 | 0 |
eGFR, estimated glomerular filtration rate; CG, Cockcroft–Gault; MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
a The CG equation was calculated with body surface area correction.
Multivariable logistic regression analysis for risk factors of ARC.
| Variables | OR (95% CI) | p-value |
|---|---|---|
| Age | 0.94 (0.91–0.96) | <0.05 |
| Male sex | 0.82 (0.3–2.29) | 0.71 |
| Diabetes mellitus | 1.95 (0.55–6.9) | 0.3 |
| Serum albumin | 0.66 (0.35–1.26) | 0.21 |
ARC, augmented renal clearance; OR, odds ratio; CI, confidence interval.
Age as a predictor of ARC using the receiver operating curves.
| AUROC | 95% CI | Optimal cut off values | Sensitivity | Specificity | PPV | NPV | |
|---|---|---|---|---|---|---|---|
| Age (years) | 0.79 | 0.68–0.91 | 63 | 68.4 | 78.9 | 76.4 | 71.4 |
ARC, augmented renal clearance; AUROC, area under the receiver operating curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.
Comparison of clinical data between survivors and non-survivors.
| Variables | Survivors (n = 253) | Non-survivors (n = 27) | p value |
|---|---|---|---|
| ARC status, n (%) | 17 (6.7) | 2 (7.4) | 0.7 |
| Age (years), median (IQR) | 74 (64–83) | 73 (65–79) | 0.64 |
| Sex, male, n (%) | 119 (53) | 16 (40.7) | 0.31 |
| Mechanical ventilation, n (%) | 95 (37.5) | 18 (66.7) | <0.05 |
| Diabetes mellitus, n (%) | 39 (15.4) | 8 (29.6) | 0.1 |
| APACHE II scores, median (IQR) | 20 (16–24) | 24 (17–28.5) | <0.05 |
| SOFA scores, median (IQR) | 5 (3–7) | 7 (5–8) | <0.05 |
| Serum albumin (g/dL), mean (SD) | 2.9 (0.75) | 2.6 (0.85) | <0.05 |
| Serum CK (IU/L), median (IQR) | 72 (35–155) | 71 (42–141) | 0.84 |
| Serum creatinine (mg/dL), median (IQR) | 0.7 (0.6–0.9) | 0.72 (0.5–0.9) | 0.58 |
| Positive blood culture, n (%) | 65 (25.7) | 6 (22.2) | 0.82 |
| Site of infection, n (%) | |||
| Lung | 101 (39.9) | 16 (59.3) | 0.06 |
| Abdomen | 75 (29.6) | 5 (18.5) | 0.27 |
| Skin and soft tissue | 37 (14.6) | 3 (11.1) | 0.78 |
| Urinary tract | 17 (6.7) | - | - |
| Surgical site | 5 (2) | 2 (7.4) | 0.14 |
| Heart | 4 (1.6) | 1 (3.7) | 0.4 |
| Central nerve system | 4 (1.6) | - | - |
| Catheter | 2 (0.8) | - | - |
| Unknown | 8 (3.2) | - | - |
| Antibiotic, n (%) | |||
| Carbapenems | 124 (49) | 13 (48.1) | 1.0 |
| Piperacillin-tazobactam | 55 (21.7) | 8 (29.6) | 0.34 |
| Ampicillin-sulbactam | 43 (17) | 2 (7.4) | 0.27 |
| Linezolid | 13 (5.1) | - | - |
| Glycopeptides | 11 (4.3) | 2 (7.4) | 0.36 |
| Clindamycin | 7 (2.8) | 2 (7.4) | 0.21 |
| Fluoroquinolones | 6 (2.4) | 1 (3.7) | 0.51 |
| Cephalosporins | 5 (2) | 1 (3.7) | 0.46 |
| Macrolides | 6 (2.4) | - | 1.0 |
| Daptomycin | 3 (1.2) | - | 1.0 |
| Others | 8 (3.2) | - | 1.0 |
ARC, augmented renal clearance; IQR, interquartile range; APACHE, Acute Physiology, and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; SD, standard deviation; CK, creatine kinase.
Multivariable logistic regression analysis for a predictor of ICU mortality.
| Variables | OR (95% CI) | p-value |
|---|---|---|
| ARC status | 0.45 (0.08–2.46) | 0.36 |
| Mechanical ventilation | 2.36 (0.97–5.75) | 0.06 |
| APACHE Ⅱ scores | 1.05 (0.99–1.12) | 0.1 |
| SOFA scores | 1.05 (0.9–1.23) | 0.52 |
| Serum albumin | 0.62 (0.34–1.1) | 0.11 |
| Lung infection | 1.85 (0.76–4.52) | 0.18 |
ICU, intensive care unit; OR, odds ratio; CI, confidence interval; ARC, augmented renal clearance; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment.